|
GB8808015D0
(en)
|
1988-04-06 |
1988-05-05 |
Ritter M A |
Chemical compounds
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
JPH06510750A
(ja)
|
1991-05-03 |
1994-12-01 |
セラジェン インク |
炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
|
|
JP3315427B2
(ja)
|
1992-03-05 |
2002-08-19 |
大日本除蟲菊株式会社 |
皮膚炎治療剤
|
|
US5714146A
(en)
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
|
EP0604693A1
(en)
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
|
RU2162711C2
(ru)
|
1993-09-07 |
2001-02-10 |
Смитклайн Бичам Корпорейшн |
Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
|
|
ATE326239T1
(de)
|
1998-09-18 |
2006-06-15 |
Dynavax Tech Corp |
Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
|
|
DK2990420T3
(en)
|
2000-05-26 |
2017-04-03 |
Immunex Corp |
USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
EP1304115B1
(en)
|
2000-07-26 |
2007-09-12 |
Hououdou Co. Ltd. |
Antipruritic compositions and compositions promoting wound healing
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20030103938A1
(en)
|
2001-05-09 |
2003-06-05 |
Alk-Abello A/S |
Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
|
|
US20050031609A1
(en)
|
2001-05-11 |
2005-02-10 |
Thomas Hultsch |
Compositions for use in treating ige-associated disorders
|
|
CA2447795A1
(en)
|
2001-05-23 |
2002-11-28 |
Duotol Ab |
Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
|
|
AR037456A1
(es)
|
2001-11-30 |
2004-11-10 |
Biogen Inc |
Anticuerpos contra proteinas quimiotacticas monocitarias
|
|
PT1527100E
(pt)
|
2002-03-29 |
2009-08-25 |
Schering Corp |
Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
|
|
WO2004047793A1
(en)
|
2002-11-26 |
2004-06-10 |
Alk-Abelló A/S |
Pharmaceutical allergen product
|
|
WO2004070011A2
(en)
|
2003-02-01 |
2004-08-19 |
Tanox, Inc. |
HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
|
|
US7923209B2
(en)
|
2003-03-14 |
2011-04-12 |
Anergis, S.A. |
Allergen peptide fragments and use thereof
|
|
BRPI0416603A
(pt)
|
2003-11-07 |
2007-01-30 |
Immunex Corp |
anticorpo que se liga ao receptor interleucina-4 (il-4) humano
|
|
AU2004309373A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
|
EP1723173B1
(en)
|
2004-02-27 |
2008-05-14 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 specific polypeptides and therapeutic uses thereof
|
|
US20090098142A1
(en)
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP5234445B2
(ja)
|
2004-10-05 |
2013-07-10 |
源一郎 杣 |
薬剤
|
|
US8030003B2
(en)
|
2004-12-07 |
2011-10-04 |
Children's Hospital Medical Center |
Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
|
|
TWI306862B
(en)
|
2005-01-03 |
2009-03-01 |
Hoffmann La Roche |
Antibodies against il-13 receptor alpha 1 and uses thereof
|
|
US8324192B2
(en)
|
2005-11-12 |
2012-12-04 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US8679545B2
(en)
|
2005-11-12 |
2014-03-25 |
The Regents Of The University Of California |
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
JP4221018B2
(ja)
|
2006-08-31 |
2009-02-12 |
トヨタ自動車株式会社 |
頭部保護エアバッグ装置
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
MY149079A
(en)
|
2006-10-02 |
2013-07-15 |
Regeneron Pharma |
High affinity human antibodies to human il-4 receptor
|
|
SI2132230T1
(sl)
|
2007-03-22 |
2014-07-31 |
Genentech, Inc. |
Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
|
|
EP2022507A1
(en)
|
2007-08-07 |
2009-02-11 |
Universität Hamburg |
Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
|
|
WO2009061819A1
(en)
|
2007-11-05 |
2009-05-14 |
The Regents Of The University Of Colorado |
Minimally-invasive measurement of esophageal inflammation
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
DE202008006598U1
(de)
|
2008-04-11 |
2008-10-02 |
Alk-Abelló A/S |
Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
|
|
US20090264392A1
(en)
|
2008-04-21 |
2009-10-22 |
Meritage Pharma, Inc. |
Treating eosinophilic esophagitis
|
|
AU2009322556A1
(en)
|
2008-12-01 |
2011-07-21 |
Children's Hospital Medical Center |
Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
|
|
US20120088814A1
(en)
|
2009-03-31 |
2012-04-12 |
Isis Pharmaceuticals, Inc. |
Methods of modulating an immune response to a viral infection
|
|
US8497528B2
(en)
|
2010-05-06 |
2013-07-30 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Method for fabricating a strained structure
|
|
CN107320722A
(zh)
|
2009-09-07 |
2017-11-07 |
Dbv技术公司 |
治疗嗜酸细胞性食管炎的方法
|
|
US8993347B2
(en)
|
2009-12-17 |
2015-03-31 |
Cornell University |
Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
|
|
EP3970726A1
(en)
|
2010-06-24 |
2022-03-23 |
ViroPharma Biologics LLC |
Methods of treatment for esophageal inflammation
|
|
NZ609557A
(en)
|
2010-10-06 |
2014-12-24 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
|
RU2453303C1
(ru)
|
2010-12-23 |
2012-06-20 |
Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") |
Фармацевтическая композиция для лечения атопического дерматита
|
|
EP2661631A4
(en)
|
2011-01-06 |
2014-05-21 |
Childrens Hosp Medical Center |
EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
|
|
US20130052190A1
(en)
|
2011-02-22 |
2013-02-28 |
Oxagen Limited |
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
|
|
US9928344B2
(en)
|
2011-06-21 |
2018-03-27 |
Children's Hospital Medical Center |
Diagnostic methods of eosinophilic esophagitis
|
|
CN103974706A
(zh)
|
2011-10-06 |
2014-08-06 |
N·V·努特里奇亚 |
嗜酸细胞性食管炎的治疗
|
|
SG11201402796SA
(en)
|
2011-12-16 |
2014-06-27 |
Atopix Therapeutics Ltd |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
|
WO2013155010A1
(en)
|
2012-04-09 |
2013-10-17 |
Children's Hospital Medical Center |
Non-invasive biomarkers for eosinophilic esophagitis
|
|
US9574004B2
(en)
|
2012-08-21 |
2017-02-21 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
|
PT3889181T
(pt)
|
2012-09-07 |
2024-05-29 |
Regeneron Pharma |
Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
|
|
US10132809B2
(en)
|
2012-10-10 |
2018-11-20 |
Rhote Island Hospital |
Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
TWI633891B
(zh)
|
2013-06-04 |
2018-09-01 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
|
|
CN111437387B
(zh)
|
2013-06-21 |
2024-10-01 |
赛诺菲生物技术公司 |
通过施用il-4r拮抗剂治疗鼻息肉症的方法
|
|
TWI682781B
(zh)
|
2013-07-11 |
2020-01-21 |
美商再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
RU2552929C1
(ru)
|
2013-11-14 |
2015-06-10 |
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" |
Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
WO2015130975A1
(en)
|
2014-02-28 |
2015-09-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an il-4r antagonist
|
|
AU2015346150B2
(en)
|
2014-11-14 |
2021-08-19 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
|
|
AU2017220184B2
(en)
|
2016-02-19 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
|
|
TWI728172B
(zh)
|
2016-08-18 |
2021-05-21 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
HUE067888T2
(hu)
|
2016-09-01 |
2024-11-28 |
Regeneron Pharma |
Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
|
|
WO2018057776A1
(en)
|
2016-09-22 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
|
|
EP4345110A3
(en)
|
2016-09-22 |
2024-06-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
CA3079946A1
(en)
|
2017-10-30 |
2019-05-09 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
US11292847B2
(en)
|
2018-05-13 |
2022-04-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an IL-4R inhibitor
|
|
CA3132587A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
US11504426B2
(en)
*
|
2019-08-05 |
2022-11-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
WO2021026205A1
(en)
|
2019-08-05 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
IL293487A
(en)
|
2019-12-09 |
2022-08-01 |
Sanofi Biotechnology |
Methods for the treatment of digitally identified il-4/il-13-related disorders
|
|
EP4153300A1
(en)
|
2020-05-22 |
2023-03-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|